-
Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production
•
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital of Colombia, to establish a joint venture named BogotáBio. The collaboration aims to strengthen local manufacturing capabilities for multiple vaccines and enhance novel vaccine research and development within the country. Colombia was one of the…
-
Longreach Group Puts Quasar Medical on the Block, Attracting Major Bidders
•
Private equity firm Longreach Group, which specializes in the Asian market, is in the process of auctioning off its medical equipment unit, Quasar Medical. According to Reuters, bidders include Boyu Capital, Hillhouse Capital, and BPEA EQT. Quasar Medical is valued at USD 600 million and reported sales of USD 30…
-
Gracell Biotechnologies’ GC012F Showcases Positive Data at ASCO Annual Meeting
•
Suzhou-based biotech firm Gracell Biotechnologies Inc., (Nasdaq: GRCL) has announced positive data for its pipeline candidate GC012F at the American Society of Clinical Oncology (ASCO) Annual Meeting. GC012F is a FasTCAR-T therapy targeting both B-cell maturation antigen (BCMA) and CD19, under development for the treatment of relapsed/refractory multiple myeloma (r/r…
-
Biosyngen’s BRG01 Earns Orphan Drug Designation from US FDA for Nasopharyngeal Carcinoma
•
Biosyngen, a leading cell therapy developer based in Guangzhou, has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its first-in-class nasopharyngeal carcinoma (NPC) cell therapy, BRG01. BRG01: A Pioneering Cell Therapy for NPCBRG01 is a genetically modified T cell product…
-
NMPA Clears Medtronic’s Corindus for Marketing of Advanced Coronary Surgery Systems
•
The National Medical Products Administration (NMPA) has granted marketing approval for the “coronary artery interventional surgery control system” and “disposable coronary artery interventional surgery control system attachment,” both developed by Medtronic Inc.’s subsidiary Corindus Inc., based in the US. Enhancing Surgical Precision and SafetyThis approval highlights a significant step forward…
-
NMPA Grants Market Approval for Lanzhou Kejin Taiji’s Carbon Ion Therapy System
•
The National Medical Products Administration (NMPA) in China has issued market approval to Lanzhou Kejin Taiji Corporation, Ltd. for its carbon ion therapy system, marking it as the second home-grown carbon ion therapy system in the country designed for the treatment of malignant solid tumors. Enhanced Features of the New…
-
HighTide Therapeutics Inc. Plans Hong Kong IPO to Fund Clinical Development
•
China-based HighTide Therapeutics Inc. has announced plans to make an initial public offering (IPO) on the Hong Kong Stock Exchange, with further details to be disclosed at a later stage. The proceeds from the IPO will be directed towards the clinical development, regulatory filing, and post-approval studies for its core…
-
Shanghai Duoning Biotechnology Partners with Wuhan Kaide Jinuo for Gene Therapy R&D
•
China’s Shanghai Duoning Biotechnology Co., Ltd has announced a strategic licensing deal with compatriot firm Wuhan Kaide Jinuo Biotechnology Co., Ltd. The collaboration aims to establish a professional research team focused on the development and research of the adenovirus technology platform, with the goal of creating an integrated solution for…
